logo-loader
viewAmarin

Amarin submits NDA for triglyceride-lowering AMR101 drug

fat_cells_350_4e80946256ae9.jpg

Amarin (NASDAQ:AMRN) announced Monday it has submitted a new drug application (NDA) to the US FDA for its AMR101 drug, intended to treat patients with very high triglycerides, or levels of a certain type of fat in the blood.

The NDA seeks approval for the marketing and sale of AMR101, which lowers the level of triglycerides in the bloodstream. The application is based on data from Amarin's two phase 3 trial of the drug, which tested for safety and efficacy.

Triglycerides are a type of fat found in the blood used to store excess and unused calories, and too much of this fat can contribute to the hardening and narrowing of your arteries, which can lead to diabetes, heart disease, and stroke. The levels of these fats in the bloodstream are classified into four categories: normal, borderline high, high, and very high.

In the U.S. alone, it is estimated that 75 million people have at least 'borderline high' levels of triglycerides, including 4 million people with 'very high' levels.

During Amarin's two phase 3 studies, AMR101 achieved all primary endpoints, including tolerability in comparison to a placebo.

"Data from our two pivotal Phase 3 studies show that, unlike other triglyceride-lowering therapies, AMR101 does not increase LDL-cholesterol [a bad form of cholesterol] and, in certain cases, significantly decreases it," said CEO Joseph S. Zakrzewski.

"The submission of this NDA moves AMR101 one step closer to commercial launch. If AMR101 is approved, we believe it can play a significant role in cardiovascular health management."

Quick facts: Amarin

Price: 4.8 USD

NASDAQ:AMRN
Market: NASDAQ
Market Cap: $1.73 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: MariMed seeing strong sales numbers with Cannabis infused...

MariMed (OTCQB: MRMD) CEO Bob Fireman and SVP of sales Ryan Crandall joined Steve Darling from Proactive to discuss the company’s new cannabis-infused hot sauce. That sauce becomes the first cannabis product produced in Puerto Rico and sold in the U.S. Crandall telling Proactive the story behind...

3 hours, 12 minutes ago

2 min read